CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
Jacobsen. Julie Mie JM; Halling. Jens Frey JF; Blom. Ida I; Moreno Martinez. Jaime J; Hald. Bjørn B; Pedersen. Kent K; Fels. Johannes Josef JJ; Snitker. Søren S; Secher. Anna A; Lundh. Sofia S; le Roux. Carel W CW; Raun. Kirsten K; Reitman. Marc L ML; Kuhre. Rune Ehrenreich RE
Summary
The study …
Abstract
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema's weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.
Study Information
pubmed
2025
2025-07-08T00:00:00.000Z
10.1038/s42255-025-01324-8
3
38